Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer

Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer is a phase 2, randomised interventional study registered as NCT07458529 by Seventh Medical Center of PLA General Hospital, with a registry enrolment figure of 50 participants, started 2026-02-10 and due to reach its primary completion in 2027-05-05. Interventions recorded: CRT+PD-1 inhibitor+Probio-M9; CRT+PD-1 inhibitor+placebo. Conditions listed: Rectal Cancer, Adenocarcinoma; Neoadjuvant Therapy; Immunotherapy; Probio-M9; Tislelizumab; Randomized. Primary outcome: pCR rate. Colorectal eligibility wording from the registry: "* Biopsy-proven rectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.